Validation of FLARE-RA, a Self-Administered Tool to Detect Recent or Current Rheumatoid Arthritis Flare

Arthritis and Rheumatology

Volumn 69, Issue 2, 2017, Pages 309-319

  Fautrel, Bruno ^a   Morel, Jacques ^b   Berthelot, Jean Marie ^c   Constantin, Arnaud ^d   De Bandt, Michel ^e   Gaudin, Philippe ^f   Maillefert, Jean Francis ^g   Meyer, Olivier ^h   Pham, Thao ⁱ   Saraux, Alain ^j   Solau Gervais, Elisabeth ^k   Vittecoq, Olivier ^l   Wendling, Daniel ^m   Erpelding, Marie Line ⁿ   Guillemin, Francis ^o  

^a SORBONNE UNIVERSITÉ   (France)

^b LAPEYRONIE HOSPITAL   (France)

^c HÔTEL DIEU   (France)

^d UNIVERSITÉ PAUL SABATIER   (France)

^e Hopital La Meynard   (France)

^f Hopital Sud CHU de Grenoble   (France)

^g HÔPITAL DU BOCAGE   (France)

^h UNIVERSITÉ PARIS DESCARTES   (France)

ⁱ HÔPITAL SAINTE MARGUERITE   (France)

^j SERVICE DE RHUMATOLOGIE   (France)

^k POITIERS UNIVERSITY HOSPITAL   (France)

^l ROUEN UNIVERSITY HOSPITAL   (France)

^m UNIVERSITÉ DE FRANCHE COMTÉ   (France)

ⁿ UNIVERSITY HOSPITAL OF NANCY   (France)

^o UNIVERSITÉ DE LORRAINE   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; C REACTIVE PROTEIN; PROTEIN ANTIBODY; RHEUMATOID FACTOR;

ADULT; ARTICLE; ASSESSMENT OF HUMANS; CONTROLLED STUDY; DAS28; DISEASE ACTIVITY; DISEASE EXACERBATION; DRUG DOSE INCREASE; ERYTHROCYTE SEDIMENTATION RATE; FATIGUE; FEMALE; FLARE RA QUESTIONNAIRE; HEALTH ASSESSMENT QUESTIONNAIRE; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; ROUTINE ASSESSMENT OF PATIENT INDEX DATA; VALIDATION STUDY; ARTHRITIS, RHEUMATOID; CLINICAL TRIAL; MULTICENTER STUDY; RECURRENT DISEASE; SELF EVALUATION;

ARTHRITIS, RHEUMATOID; DIAGNOSTIC SELF EVALUATION; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SYMPTOM FLARE UP;

EID: 85010858539     PISSN: 23265191     EISSN: 23265205     Source Type: Journal    
DOI: 10.1002/art.39850     Document Type: Article

References (41)

1. Smolen JS, Landewe R, Breedveld FC, Buch M, Burmester G, Dougados M, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 2014;73:492–509.
2. Dougados M, Soubrier M, Perrodeau E, Gossec L, Fayet F, Gilson M, et al. Impact of a nurse-led programme on comorbidity management and impact of a patient self-assessment of disease activity on the management of rheumatoid arthritis: results of a prospective, multicentre, randomised, controlled trial (COMEDRA). Ann Rheum Dis 2014. E-pub ahead of print.
3. Gaujoux-Viala C, Gossec L, Cantagrel A, Dougados M, Fautrel B, Mariette X, et al. Recommendations of the French Society for Rheumatology for managing rheumatoid arthritis. Joint Bone Spine 2014;81:287–97.
4. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO III, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 2010;62:2569–81.
5. Aga AB, Lie E, Uhlig T, Olsen IC, Wierod A, Kalstad S, et al. Time trends in disease activity, response and remission rates in rheumatoid arthritis during the past decade: results from the NOR-DMARD study 2000-2010. Ann Rheum Dis 2015;74:381–8.
6. Bingham CO III, Pohl C, Woodworth TG, Hewlett SE, May JE, Rahman MU, et al. Developing a standardized definition for disease “flare” in rheumatoid arthritis (OMERACT 9 Special Interest Group). J Rheumatol 2009;36:2335–41.
7. Bingham CO III, Alten R, Bartlett SJ, Bykerk VP, Brooks PM, Choy E, et al. Identifying preliminary domains to detect and measure rheumatoid arthritis flares: report of the OMERACT 10 RA Flare Workshop. J Rheumatol 2011;38:1751–8.
8. Alten R, Pohl C, Choy EH, Christensen R, Furst DE, Hewlett SE, et al. Developing a construct to evaluate flares in rheumatoid arthritis: a conceptual report of the OMERACT RA Flare Definition Working Group. J Rheumatol 2011;38:1745–50.
9. Bartlett SJ, Hewlett S, Bingham CO III, Woodworth TG, Alten R, Pohl C, et al. Identifying core domains to assess flare in rheumatoid arthritis: an OMERACT international patient and provider combined Delphi consensus. Ann Rheum Dis 2012;71:1855–60.
10. Berthelot JM, de Bandt M, Morel J, Benatig F, Constantin A, Gaudin P, et al. A tool to identify recent or present rheumatoid arthritis flare from both patient and physician perspectives: the “FLARE” instrument. Ann Rheum Dis 2012;71:1110–6.
11. Bykerk VP, Lie E, Bartlett SJ, Alten R, Boonen A, Christensen R, et al. Establishing a core domain set to measure rheumatoid arthritis flares: report of the OMERACT 11 RA Flare Workshop. J Rheumatol 2014;41:799–809.
12. Berthelot JM, Blanchais A, Marhadour T, le Goff B, Maugars Y, Saraux A. Fluctuations in disease activity scores for inflammatory joint disease in clinical practice: do we need a solution? Joint Bone Spine 2009;76:126–8.
13. Smolen JS, Nash P, Durez P, Hall S, Ilivanova E, Irazoque-Palazuelos F, et al. Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial. Lancet 2013;381:918–29.
14. Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight−joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995;38:44–8.
15. Welsing PM, Landewe RB, van Riel PL, Boers M, van Gestel AM, van der Linden S, et al. The relationship between disease activity and radiologic progression in patients with rheumatoid arthritis: a longitudinal analysis. Arthritis Rheum 2004;50:2082–93.
16. Pincus T, Swearingen CJ, Bergman MJ, Colglazier CL, Kaell AT, Kunath AM, et al. RAPID3 (Routine Assessment of Patient Index Data) on an MDHAQ (Multidimensional Health Assessment Questionnaire): agreement with DAS28 (Disease Activity Score) and CDAI (Clinical Disease Activity Index) activity categories, scored in five versus more than ninety seconds. Arthritis Care Res (Hoboken) 2010;62:181–9.
17. Pincus T, Furer V, Keystone E, Yazici Y, Bergman MJ, Luijtens K. RAPID3 (Routine Assessment of Patient Index Data 3) severity categories and response criteria: similar results to DAS28 (Disease Activity Score) and CDAI (Clinical Disease Activity Index) in the RAPID 1 (Rheumatoid Arthritis Prevention of Structural Damage) clinical trial of certolizumab pegol. Arthritis Care Res (Hoboken) 2011;63:1142–9.
18. Cheung PP, Ruyssen-Witrand A, Gossec L, Paternotte S, le Bourlout C, Mazieres M, et al. Reliability of patient self-evaluation of swollen and tender joints in rheumatoid arthritis: a comparison study with ultrasonography, physician, and nurse assessments. Arthritis Care Res (Hoboken) 2010;62:1112–9.
19. Guillemin F, Bombardier C, Beaton D. Cross-cultural adaptation of health-related quality of life measures: literature review and proposed guidelines. J Clin Epidemiol 1993;46:1417–32.
20. Boers M, Brooks P, Strand CV, Tugwell P. The OMERACT filter for Outcome Measures in Rheumatology. J Rheumatol 1998;25:198–9.
21. Lassere MN. A users guide to measurement in medicine. Osteoarthritis Cartilage 2006;14 Suppl A:A10–3.
22. Mokkink LB, Terwee CB, Knol DL, Stratford PW, Alonso J, Patrick DL, et al. The COSMIN checklist for evaluating the methodological quality of studies on measurement properties: a clarification of its content. BMC Med Res Methodol 2010;10:22.
23. Mokkink LB, Terwee CB, Gibbons E, Stratford PW, Alonso J, Patrick DL, et al. Inter-rater agreement and reliability of the COSMIN (COnsensus-based Standards for the selection of health status Measurement INstruments) checklist. BMC Med Res Methodol 2010;10:82.
24. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315–24.
25. Pincus T, Strand V, Koch G, Amara I, Crawford B, Wolfe F, et al. An index of the three core data set patient questionnaire measures distinguishes efficacy of active treatment from that of placebo as effectively as the American College of Rheumatology 20% response criteria (ACR20) or the Disease Activity Score (DAS) in a rheumatoid arthritis clinical trial. Arthritis Rheum 2003;48:625–30.
26. Fries JF, Spitz PW, Young DY. The dimensions of health outcomes: the health assessment questionnaire, disability and pain scales. J Rheumatol 1982;9:789–93.
27. Gossec L, Paternotte S, Aanerud GJ, Balanescu A, Boumpas DT, Carmona L, et al. Finalisation and validation of the rheumatoid arthritis impact of disease score, a patient-derived composite measure of impact of rheumatoid arthritis: a EULAR initiative. Ann Rheum Dis 2011;70:935–42.
28. Horn JL. A rationale and test for the number of factors in factor analysis. Psychometrika 1965;30:179–85.
29. Coste J, Bouée S, Ecosse E, Leplège A, Pouchot J. Methodological issues in determining the dimensionality of composite health measures using principal component analysis: case illustration and suggestions for practice. Qual Life Res 2005;14:641–54.
30. Masters G. A rasch model for partial credit scoring. Psychometrika 1982;47:149–74.
31. Andrich D, Douglas D. Reliability: distinctions between item consistency and subject separation with the simple logistic model [poster]. Presented at the Annual Meeting of the American Educational Research Association; 1977; New York.
32. Teresi JA, Fleishman JA. Differential item functioning and health assessment. Qual Life Res 2007;16 Suppl 1:33–42.
33. Hewlett S, Sanderson T, May J, Alten R, Bingham CO III, Cross M, et al. “I'm hurting, I want to kill myself”: rheumatoid arthritis flare is more than a high joint count: an international patient perspective on flare where medical help is sought. Rheumatology (Oxford) 2012;51:69–76.
34. Furst DE, Breedveld FC, Kalden JR, Smolen JS, Burmester GR, Sieper J, et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007. Ann Rheum Dis 2007;66 Suppl 3:iii2–22.
35. Hewlett S, Mitchell K, Haynes J, Paine T, Korendowych E, Kirwan JR. Patient-initiated hospital follow-up for rheumatoid arthritis. Rheumatology (Oxford) 2000;39:990–7.
36. Kirwan J, Hewlett S, Mitchell K, Hehir M, Pollock J, Blair P, et al. RCT of patient-initiated review versus regular physician-initiated follow-up in rheumatoid arthritis, extended to 6 years [abstract]. Ann Rheum Dis 2004;63 Suppl 1:75.
37. Hewlett S, Kirwan J, Pollock J, Mitchell K, Hehir M, Blair PS, et al. Patient initiated outpatient follow up in rheumatoid arthritis: six year randomised controlled trial. BMJ 2005;330:171.
38. Tanaka Y, Hirata S, Kubo S, Fukuyo S, Hanami K, Sawamukai N, et al. Discontinuation of adalimumab after achieving remission in patients with established rheumatoid arthritis: 1-year outcome of the HONOR study [published erratum appears in Ann Rheum Dis 2016;75:e46]. Ann Rheum Dis 2015;74:389–95.
39. Tanaka Y, Takeuchi T, Mimori T, Saito K, Nawata M, Kameda H, et al. Discontinuation of infliximab after attaining low disease activity in patients with rheumatoid arthritis: RRR (remission induction by Remicade in RA) study. Ann Rheum Dis 2010;69:1286–91.
40. Brocq O, Millasseau E, Albert C, Grisot C, Flory P, Roux CH, et al. Effect of discontinuing TNFα antagonist therapy in patients with remission of rheumatoid arthritis. Joint Bone Spine 2009;76:350–5.
41. Den Broeder AA, van der Maas A, van den Bemt BJ. Dose de-escalation strategies and role of therapeutic drug monitoring of biologics in RA. Rheumatology (Oxford) 2010;49:1801–3.